Article Abstract:
A prospective trial study for the Diabetes Reduction Assessment with ramipril and rosiglitazone Medication (DREAM) was conducted to evaluate whether ramipril reduces the risk of diabetes in people who have impaired fasting glucose levels or impaired glucose tolerance but who are at low risk for cardiovascular events. Among persons with impaired fasting glucose levels or impaired glucose tolerance, the use of ramipril for 3 years does not significantly reduce the incidence of diabetes or death but does significantly increase regression to normoglycemia.
User Contributions:
Comment about this article or add new information about this topic:
Article Abstract:
Many patients with risk factors for heart disease may benefit from ACE inhibitors. ACE inhibitors block the activity of angiotensin II. This is a natural substance in the body that has a beneficial effect provided that it is not produced in excess amounts. The first ACE inhibitor was developed in 1977 but by the 1980s, it was clear that they had many actions beyond their ability to lower blood pressure. They seem to protect the heart, kidneys, and blood vessels from long-term activation of the renin-angiotensin-aldosterone system.
User Contributions:
Comment about this article or add new information about this topic:
Article Abstract:
The ACE inhibitor ramipril appears to reduce the risk of heart disease in people with diabetes or pre-existing blood vessel disease. Researchers randomly assigned 9,297 people who had no evidence of heart disease but had diabetes or blood vessel disease to take ramipril or a placebo for an average of five years. Those who took ramipril had a lower risk of death, heart attack, heart failure, and cardiac arrest than those in the placebo group, although the reductions were relatively small.
User Contributions:
Comment about this article or add new information about this topic: